Association of apolipoprotein B and incidence of metabolic syndrome in Korean men: A 5-years%26apos; follow-up study

作者：Ryoo Jae Hong; Park Sung Keun^*

来源：Atherosclerosis, 2013, 226(2): 496-501.

DOI：10.1016/j.atherosclerosis.2012.11.024

• Apolipoprotein B
• Metabolic syndrome

Background and objective: There have been reports for the association between elevated serum apolipoprotein B (ApoB) and several cardiometabolic disorders. However, it remains unclear whether serum ApoB level predicts the development of metabolic syndrome (MetS). Accordingly, we carried out a prospective study to evaluate the longitudinal effects of baseline serum ApoB levels on the development of MetS. %26lt;br%26gt;Patients and methods: A cohort of 25,193 healthy Korean men without MetS had been followed up prospectively. Baseline serum ApoB levels were categorized to following quintiles (quintile 1-5: %26lt;76.4, 76.4-88.4, 88.4-99.5, 99.5-113.0, %26gt;= 113.0). We evaluated the differences in the incidence of MetS according to quintiles of serum ApoB levels. Cox proportional hazards models were used to calculate the adjusted hazard ratios (HRs) for MetS. %26lt;br%26gt;Results: During follow-up, 5407 (21.5%) cases developed MetS between 2006 and 2010. Incidence of MetS increased according to quintiles of serum ApoB levels [quintile 1-5: 9.1%, 16.4%, 22.1%, 27.3%, 36.4%, respectively (P for trend %26lt;0.001)]. Even after adjusting for various covariates including non-HDL-cholesterol, the hazard ratios (95% CI) for MetS increased in proportion to the quintiles of serum ApoB levels, compared to quintile 1 [quintile 2-5: 1.64 (1.43-1.89), 1.98 (1.71-2.31), 2.32 (1.96-2.75) and 2.92 (2.37-3.60), respectively (P for trend %26lt;0.001)]. These associations were apparent still in the clinically relevant subgroup analyses. %26lt;br%26gt;Conclusions: Serum ApoB levels predict MetS, independent of baseline confounding variables including non-HDL-cholesterol.

• 出版日期2013-2